Latest Probiotics News

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

BPH Global Limited secured $1.1 million in a recent placement and reported robust growth in its Indonesian seaweed operations, alongside promising advances in innovative seaweed-based products and strategic regional partnerships.

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.

Terragen Holdings expands its probiotic product range into beef and lamb feedlots, secures key international approvals, and progresses large-scale trials while maintaining a $3 million cash reserve.

Biome Australia Limited has reported a record quarterly revenue of $5.94 million for Q1 FY26, marking a 40% increase year-over-year and its seventh consecutive quarter of positive EBITDA. The company’s strong cash flow and sustained margins underscore its growth momentum.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

Biome Australia Limited has reported a record-breaking $5.94 million in sales revenue for Q1 FY26, surpassing forecasts and accelerating toward its ambitious Vision 27 revenue goals.

Clover Corporation posted a robust 38% revenue increase to $86 million in FY25, driven by product innovation and operational gains, while declaring a final dividend. The company’s cautious outlook for FY26 reflects ongoing regulatory and production challenges.

BPH Global has raised $1.1 million through a private placement to expand its Indonesian seaweed operations and advance innovative R&D projects, positioning itself for growth in sustainable aquaculture and blue economy solutions.

BPH Global has completed an 18-week R&D collaboration with Singapore Polytechnic, developing two innovative green seaweed kefir beverages that combine health benefits with commercial promise.